{
    "organizations": [],
    "uuid": "1528d332d54965d22f7fcb20cef0c7d15a6e964d",
    "author": "Charley Grant",
    "url": "https://www.wsj.com/articles/can-celgene-save-itself-1519900201",
    "ord_in_thread": 0,
    "title": "Can Celgene Save Itself?",
    "locations": [],
    "highlightText": "",
    "language": "english",
    "persons": [],
    "text": "Celgene’s hard-won status as a biotech blue chip has unraveled in just months.\nThe latest blow came Tuesday when Celgene announced that the Food and Drug Administration took a rare step and declined to review Celgene’s application for its experimental multiple sclerosis drug, Ozanimod. Shares fell 9% in response on Wednesday. Drugs that receive such treatment often fail to ever reach the market; those that do often sell poorly.\nThat... ",
    "published": "2018-03-01T13:30:00.000+02:00",
    "crawled": "2018-03-01T18:53:30.027+02:00",
    "highlightTitle": "",
    "preprocessed_text": [
        "celgene",
        "status",
        "biotech",
        "blue",
        "chip",
        "unraveled",
        "month",
        "latest",
        "blow",
        "came",
        "tuesday",
        "celgene",
        "announced",
        "food",
        "drug",
        "administration",
        "took",
        "rare",
        "step",
        "declined",
        "review",
        "celgene",
        "application",
        "experimental",
        "multiple",
        "sclerosis",
        "drug",
        "ozanimod",
        "share",
        "fell",
        "response",
        "wednesday",
        "drug",
        "receive",
        "treatment",
        "often",
        "fail",
        "ever",
        "reach",
        "market",
        "often",
        "sell",
        "poorly"
    ]
}